KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Beginning Cash Balance: 2010-2024

Historic Beginning Cash Balance for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $75.1 million.

  • Supernus Pharmaceuticals' Beginning Cash Balance rose 175.03% to $143.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.2 million, marking a year-over-year decrease of 68.18%. This contributed to the annual value of $75.1 million for FY2024, which is 19.40% down from last year.
  • Supernus Pharmaceuticals' Beginning Cash Balance amounted to $75.1 million in FY2024, which was down 19.40% from $93.1 million recorded in FY2023.
  • Supernus Pharmaceuticals' Beginning Cash Balance's 5-year high stood at $288.6 million during FY2021, with a 5-year trough of $75.1 million in FY2024.
  • Over the past 3 years, Supernus Pharmaceuticals' median Beginning Cash Balance value was $93.1 million (recorded in 2023), while the average stood at $123.9 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Beginning Cash Balance surged by 59.13% in 2021 and then plummeted by 54.23% in 2023.
  • Supernus Pharmaceuticals' Beginning Cash Balance (Yearly) stood at $181.4 million in 2020, then skyrocketed by 59.13% to $288.6 million in 2021, then declined by 29.52% to $203.4 million in 2022, then tumbled by 54.23% to $93.1 million in 2023, then dropped by 19.40% to $75.1 million in 2024.